Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Breakfast News - Strongbow Exploration; ASA International; Sirius Minerals and more...

Breakfast News - Strongbow Exploration; ASA International; Sirius Minerals and more...

Small Cap Breakfast

Set menu

AIM:

Total number of AIM Companies (Incl Susp):

934*

Total number of AIM Companies trading:

877*

*as at close of business  19 June 2018

Standard List**  of Main Market:

Total number of Standard List Companies

(Incl Susp):

137*

Total number of Standard List Companies trading:

124*

*as at close of business  20 June 2018

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):

85*

Total number of NEX Growth Market Companies trading:

83*               

*as at close of business  19 June 2018

*A corporate client of Hybridan LLP

**  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity


 
Dish of the day

Anexo (AIM:ANX) -specialist integrated credit hire and legal services group. Offer raising £25m at 100p, market cap £110m.  Calendar 2017 revenue of £44.8 million and £14.6 million Profit Before Tax.

Tekmar (AIM:TGP)— technology provider of protection systems for subsea cable, umbilical and flexible pipes and offshore engineering services—Offshore wind farms and Oil & Gas. Revenue of £21.9m and Adjusted EBITDA of £4.9m. £61.8m raised at 130p. Mkt cap c.£65m. 

Off the menu  

No leavers Today

What’s cooking in the IPO kitchen?

NEX Exchange

GoTech Group– AIM shell moving to NEX. the Company’s Investment Strategy will be to initially effectively become a UK, Canadian and Australian-focused medicinal cannabis and related products’ index tracker and investor. Due 25 Jun.

Sovereign Mines of Africa PLC  to be renamed The Barkby Group PLC after the acquisition of Turf to Table Ltd will join the NEX Exchange on 26 June 2018 after raising £547k at 9p with market cap of £3.42m

AIM

RA International is a leading provider of services to remote locations in Africa and the Middle East looking to join AIM raising £18.8m and 56p, market cap of £97.2m. Expected 29 June

Cake Box Holdings—franchise retailer of cakes with a growing store base across the UK looking to join AIM, Offer tbc, expected late June

Mind Gym. Behavioural science business that uses scalable proprietary products to deliver human capital and business improvement solutions to large corporations. Offer TBA. Due 28 June

i-nexus—develops and provides strategy execution software to assist global enterprises in effective execution of their strategic plans and initiatives looking to jon AIM. Offer raising £10m at 79p, market cap of £23.36m, expected 21 June

Yellow Cake will use its expertise to generate value through the ownership of physical U3O8 (Uranium) together with a range of activities and opportunities connected with owning physical U3O8. Acquiring supply contract for up to $170m. Offer TBA.

Knights Group— UK regional legal and professional services businesses. FYApr18 rev  £34.9m and adjusted operating profit was £6.8m excluding Turner Parkinson (acquiring on IPO).  Offer TBA, expected 29 June.

TransGlobe Energy Corporation—an independent international upstream oil and gas company with headquarters in Calgary, Canada is looking to join AIM. No Capital to be raised, market cap of £131m. Expected 29 June

Strongbow Exploration (TSX:SBW) intends to dual list on AIM.  Holds rights to the South Crofty underground tin mine, a former producing tin mine located in the towns of Pool and Camborne, Cornwall . The project is estimated to require the Company to raise £25 million over the next 18 months to progress to a production decision. Offer TBS. Due June.

 

Main Market (Premium)

ASA International— “one of the world's largest and most profitable international microfinance institutions, which aims to enhance financial inclusion among low-income populations throughout Asia and Africa in a socially responsible manner”.  Secondary sell down. No primary. Due July. Offer TBA

Ashoka India Equity Investment Trust—Target raise £100m. India  focussed high conviction, long-only IT. Due mid July.

Utilico Global Income—  new actively managed income investment trust raising up to £100m. Due 22 June.

Amigo Holdings—The pioneer of guarantor loans now lending c. £470m per annum. Secondary Sell down. Pricing TBA

 

Main Market (Standard)

Argo Blockchain. UK-based provider of cryptocurrency mining services. Looking to raise £20m. Offer TBA. Its main operations went live on 11 June 2018. Offer TBA.

Main Market (Specialist Funds)

Tritax EuroBox raising up to £300m.  “Will provide an opportunity for investors to gain exposure to a portfolio of well located Continental European logistics real estate assets”. Due 9 July.



Breakfast Buffet

Elektron Technology (LON:EKT) 41p £73.5m

Ahead of its Annual General Meeting on Weds 20 June 2018, Elektron Technology, the technology group, provides an update on recent trading.

Bulgin's order book is significantly stronger than a year ago with both the order book and YTD orders at new record levels with sales at the half year expected to be at least £1m ahead of last year's £12.5m. As a result of continued strong demand and despite order visibility of around 12 weeks, the Board now expects sales for the full year to be ahead of the £27.3m achieved last year.

Checkit, the Group's SaaS model business, continues to make strong progress and is in advanced discussions with a number of global businesses with a view to adoption of Checkit's disruptive technology.

Elektron Eye Technology continues to trade in line with expectations.

Elektron expects to provide an update on current year first half sales and cash in early August.

Sirius Minerals (LON:SXX) 32.67p £1.5bn

Binding take or pay offtake agreement to supply POLY4 (multi-nutrient fertilizer) to Intercontinental Trade DMCC Dubai.

ITL Trading is a global trading company with an active presence in Europe, Africa, the Middle East and Asia. It specialises in supplying Nigeria and West African clients with globally sourced products and services that are critical to laying the foundations for a modern economy. ITL Trading has been in business for over 25 years, and is headquartered in Dubai. The supply agreement is a seven-year agreement from first production, for volumes of POLY4 increasing to 350,000 tonnes per annum in year four and provides for exclusive marketing rights into Nigeria. The Company's peak contracted sales volumes has increased from 4.4 Mtpa to 4.7 Mtpa.

Best of the Best  (LON:BOTB) 275p £27.7m

FY Apr 18 results. Best of the Best plc runs competitions online to win cars and other prizes.

Total Revenue of £12.95m with like-for-like revenue up 13.3% to £12.25m (2017: £10.81m)

PBT increased by 5.8% to £1.60m(2017: £1.51m)

Online revenue of £10.87m with like-for-like online revenue up 23.0% to £10.28mm(2017: £8.36m) representing 83.9% of like-for-like revenue

“BOTB has delivered increased revenues and profits slightly ahead of management's expectations and remains strongly cash generative.  We believe the business is well positioned for the new financial year, which has started encouragingly, and I look forward to updating shareholders on further progress in due course.”

mporium Group (LON:MPM) 7.5p £44.1m

“The technology firm delivering event-driven marketing, announced that its proprietary IMPACT technology was used to deliver high levels of performance across the Samsung S9 phone launch campaign [via the agency Performics], as well as being part of further, ongoing campaigns for the global brand.

Mporium's technology was used as part of the S9 launch, to identify and monetise micro-moments of opportunity, delivering a high return on investment and, ultimately, an improved performance for the campaign. IMPACT is now being used across a wide range of Samsung product campaigns.

Genedrive (LON:GDR) 36.5p £6.9m

The near patient molecular diagnostics company, today announces its receipt of a multi-partner grant award from the UK National Institute for Health Research's Invention for Innovation programme, for the development and implementation of a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss in newborn children.  A Genedrive® test is targeted to allow genetic results to be available within an hour, allowing alternative antibiotics to be used and thus avoiding the potential life changing adverse reaction to gentamicin (prescribed to c. 90k babies per year in the UK on intensive care units.).  Antibiotic treatment should start within the first hour after admission, but current lab-based genetic tests are not able to return actionable results within that timeframe.

Redt Energy  (LON:RED) 5.95p £42.8m

“redT energy plc, the energy storage solutions company, today formally launched its third generation flow machine at eeS Europe in Munich, Europe's largest and most international exhibition for batteries and energy storage systems.

Featuring a new, proprietary system design, with multiple patents filed, this new product offers improved charge/discharge characteristics and increased efficiency within a more compact format. redT's Gen 3 machine has been specifically engineered as a high performance, distributed energy infrastructure asset.”

Clearstar (LON:CLSU) 55p £20m

The technology and service provider to the background check industry, announces that its ClearMD mobile drug testing solution is now integrated with Abbott Laboratories (formerly Alere), a leading global provider of healthcare diagnostics. This significantly expands the number of test collection sites where ClearStar's mobile solution for medical test ordering can be used. In addition to the Company's existing integrations with LabCorp and Quest Diagnostics, ClearStar is now the only provider offering paperless medical screening with a fully customisable user platform across all three of the major laboratories in the US.

CAP-XX (LON:CPX) 9.2p £27.5m

As it approaches the end of its financial year ending 30 June 2018, the Company has received a sharp increase in enquiry levels across all product ranges, including its recently announced 3 Volt technology. Total enquiries, if converted to orders, would amount to annualised sales in excess of US$20m per annum, including over US$2m which has already been classed as design wins, covering over 70 projects for cylindrical and automotive supercapacitors; small IoT and Thinline supercapacitors; and the new 3 Volt prismatic supercapacitors that are in development.

H2 revenues more than double H1 at A$3.35m and H2 approaching break even at the EBITDA level vs A$1.5m loss in H1. Cash of A$1.8m.

Mercia Technologies (LON:MERC) 34.2p £106.4m

“The national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions, is pleased to announce that its direct investment, VirtTrade Ltd ("VirtTrade"), has secured a partnership with Formula 1 to join its growing roster of digital initiatives, aimed at providing innovative new methods for fan engagement in the sport.

VirtTrade is a developer and publisher of digital trading cards and works with licensors to create high quality engagement apps for fans. The VirtTrade platform allows fans around the world to pursue their passions by collecting digital cards, making trades and competing in games.”

Last NAV/share reported 41.1p.

Deltex Medical (LON:DEMG) 1.3p £6.4m

AGM statement from the specialist in Oesophageal Doppler Monitoring. Highlights three focus areas.

* extending Deltex Medical's product offering on the TrueVue platform to facilitate sales into a broader number of clinical areas around the world to increase the size of the Group's addressable market;

* focussing on the effectiveness of the Group's sales processes to maximise the sales of high margin, ODM disposable probes; and

* husbanding Deltex Medical's cash resources while moving towards cash generation.

Hybridan LLP Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document. This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute  “independent investment research” for the purposes of the Financial Services Authority (FSA) rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers  and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the FSA) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons.  For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the FSA). Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions. Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange.  Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

 

Proactive Investors Limited Disclaimer

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

 

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use